Enhance existing research programs and develop priority programs for the future.
Strategy 2.1 - We will strengthen the quality and impact of our basic, translational, clinical and population-based research by providing superior leadership, infrastructure and resources, and by optimizing efficiencies and benefiting from rigorous internal and external reviews.
Strategy 2.2 - We will lead in the personalization of cancer diagnosis and treatment by detecting and targeting specific genetic and molecular abnormalities in a patient’s cancer and the tissue microenvironment, enhancing immune responses, and improving targeted radiation and surgical treatments.
Strategy 2.3 - We will invest and redirect resources to seize emerging research opportunities and to reward excellence and innovation. Our investigators will leverage institutional research support by continuing to increase funding from extramural sources.
Strategy 2.4 - We will create new research programs and strategically expand or contract existing programs based on scientific merit and contribution to our mission.
Strategy 2.5 - We will improve our information systems, bioinformatics and computational capabilities in order to collect, integrate and analyze large clinical and research databases, and to generate new knowledge and enhance its usefulness.
Strategy 2.6 - We will investigate ways to reduce and ameliorate undesired short- and long-term effects of cancer and its treatment, and to enhance the lives of cancer survivors.
Strategy 2.7 - We will convert scientific discoveries into useful products and devices through enhanced technology development and transfer.